Analysts Offer Insights on Healthcare Companies: Ocugen (OCGN), 9 Meters Biopharma (NMTR) and TCR2 Therapeutics (TCRR)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Ocugen (OCGN – Research Report), 9 Meters Biopharma (NMTR – Research Report) and TCR2 Therapeutics (TCRR – Research Report).

Ocugen (OCGN)

Mizuho Securities analyst Uy Ear maintained a Buy rating on Ocugen today and set a price target of $5.00. The company’s shares closed last Wednesday at $1.94, close to its 52-week low of $1.67.

According to TipRanks.com, Ear is a 1-star analyst with an average return of -11.8% and a 30.8% success rate. Ear covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, Satsuma Pharmaceuticals, and ACADIA Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ocugen with a $8.67 average price target.

See today’s best-performing stocks on TipRanks >>

9 Meters Biopharma (NMTR)

Maxim Group analyst Naz Rahman maintained a Hold rating on 9 Meters Biopharma yesterday. The company’s shares closed last Wednesday at $0.22, close to its 52-week low of $0.20.

According to TipRanks.com, Rahman has 0 stars on 0-5 stars ranking scale with an average return of -38.2% and a 16.2% success rate. Rahman covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Neurosense Therapeutics Ltd., and Processa Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for 9 Meters Biopharma with a $3.67 average price target.

TCR2 Therapeutics (TCRR)

In a report released today, Mara Goldstein from Mizuho Securities maintained a Buy rating on TCR2 Therapeutics, with a price target of $20.00. The company’s shares closed last Wednesday at $1.85, close to its 52-week low of $1.69.

According to TipRanks.com, Goldstein is a 1-star analyst with an average return of -0.9% and a 31.9% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Corvus Pharmaceuticals.

TCR2 Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $12.33.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on OCGN:

• Wedbush Sticks to Their Buy Rating for Endava (DAVA)
• Analysts’ Top Healthcare Picks: Ocugen (OCGN), Moleculin Biotech (MBRX)
• American Express Stock (NYSE:AXP): Too Much Negativity Already Baked In
• Johnson & Johnson (NYSE: JNJ) to Name New Company Post Spin-Off as Kenvue
• Bioline RX Ltd Sponsored ADR (BLRX) Gets a Buy from H.C. Wainwright